Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Klöckl, MC; Kasparek, AK; Riedl, JM; Moik, F; Mollnar, S; Stotz, M; Szkandera, J; Terbuch, A; Gerger, A; Niedrist, T; Pichler, M; Bauernhofer, T; Schilcher, G; Zitta, S; Rosenkranz, AR; Friedl, C; Stöger, H; Posch, F.
Estimation versus measurement of the glomerular filtration rate for kidney function assessment in patients with cancer undergoing cisplatin-based chemotherapy.
Sci Rep. 2020; 10(1):11219 Doi: 10.1038/s41598-020-68010-5 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Posch Florian
Co-Autor*innen der Med Uni Graz
Bauernhofer Thomas
Gerger Armin
Kasparek Anne-Katrin
Moik Florian
Niedrist Tobias
Pichler Martin
Riedl Jakob
Rosenkranz Alexander
Schilcher Gernot
Stöger Herbert
Stotz Michael
Szkandera Joanna
Terbuch Angelika
Zitta Sabine

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Glomerular filtration rate (GFR) assessment is indicated before every administration of cisplatin. The optimal modality for this purpose [GFR measurement by urinary Creatinine Clearance (uCrCl) versus GFR estimation (eGFR) by the CKD-EPI formula versus both] is unclear. We investigated whether eGFR only is safe in this setting. Paired uCrCl and eGFR determinations from 470 cisplatin cycles from 121 patients were analyzed [median age: 55 years; most frequent tumor site: genitourinary (45%); palliative treatment: n = 41 (34%)]. Primary endpoint was the proportion of cycles with uCrCl < 50 ml/min/1.73m2 and eGFR ≥ 50 ml/min/1.73m2 (i.e. a "false negative" result when only determining eGFR). The primary endpoint occurred in 8 of 470 cisplatin cycles (1.7%, 95%CI 0.5-2.9). In all 8 events, uCrCl was lower than eGFR (mean uCrCl vs. eGFR: 43 versus 112 ml/min/1.73m2). The uCrCl was re-measured in all patients, and showed normal results in all but 1 patient. None of these events precluded the administration of cisplatin at the planned date, and no subsequent cases of acute nephrotoxicity occurred. Overall agreement between uCrCl and eGFR was low, with qualitative analysis suggesting frequent incompliance with 24-h urine collection. We conclude that an eGFR is sufficient for assessing kidney function in patients with cancer undergoing cisplatin therapy.
Find related publications in this database (using NLM MeSH Indexing)
Acute Kidney Injury - blood, chemically induced, diagnosis, urine
Adult - administration & dosage
Cisplatin - adverse effects
Creatinine - blood, metabolism, urine
Female - administration & dosage
Glomerular Filtration Rate - drug effects, physiology
Humans - administration & dosage
Kidney - drug effects, physiopathology
Male - administration & dosage
Middle Aged - administration & dosage
Neoplasms - blood, drug therapy, urine
Renal Elimination - physiology
Retrospective Studies - administration & dosage

© Med Uni Graz Impressum